Wu Haotian, Chen Zhaoyu, Wang Ou, Jiang Tong, Huang Jian, Wang Jun, Lin Jianhao
Peking University Arthritis Clinic and Research Center, Peking University People's Hospital, Xicheng, Beijing 100044, China.
Key Laboratory of Trace Element Nutrition of National Health Commission of People's Republic of China, National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Xicheng, Beijing 100050, China.
Nutrients. 2024 Dec 16;16(24):4343. doi: 10.3390/nu16244343.
We aimed to explore the possible effects of Kashin-Beck disease (KBD) on the risk of sarcopenia and its possible interaction in the association between the risk of sarcopenia and element concentration.
This cross-sectional study was conducted among individuals 18-75 years old in Qamdo, a KBD-endemic area. All individuals received physical and radiological examinations before recruitment. Patients with KBD were enrolled in the KBD group based on a diagnosis of national criteria WS/T 207-2010. Healthy individuals without KBD were enrolled in the non-KBD group. Participants with a history of element supplements, other severe musculoskeletal diseases, or organ dysfunctions were excluded. We adopted WOMAC scores for the assessment of musculoskeletal conditions and SARC-F scores for the risk of sarcopenia. Patients with SARC-F ≥ 4 were at risk of sarcopenia. Serum element concentrations were analyzed by inductively coupled plasma mass spectrometry. Dose-relationship effects of clinical scores and element concentrations on the risk of sarcopenia were determined in correlation analysis. Risk factors were identified using univariate and multivariate regression. Statistical analysis was conducted using R software.
A total of 65 patients with KBD and 38 participants without KBD were enrolled in the analysis. After propensity score matching, population characteristics were comparable in the two groups, and the incidence of SARC-F ≥ 4 was determined to be higher in the KBD group ( = 0.002). The WOMAC scores were correlated with SARC-F scores in the KBD group ( < 0.001) and non-KBD ( < 0.001) group, respectively. Further analysis proved that KBD was the independent risk factor for the risk of sarcopenia ( = 0.014). Moreover, high Selenium concentrations were associated with a low risk of sarcopenia in the non-KBD group ( = 0.047), while this association was not observed in the KBD group ( = 0.239).
KBD as an independent risk factor increased the risk of sarcopenia for patients. Although high Se concentration was associated with a low risk of sarcopenia in participants without KBD, this association was not observed in those with KBD.
我们旨在探讨大骨节病（KBD）对肌肉减少症风险的可能影响及其在肌肉减少症风险与元素浓度关联中的可能相互作用。
这项横断面研究在大骨节病流行地区昌都18至75岁的个体中进行。所有个体在招募前均接受了体格检查和放射学检查。根据国家诊断标准WS/T 207 - 2010确诊为大骨节病的患者被纳入大骨节病组。无大骨节病的健康个体被纳入非大骨节病组。排除有元素补充史、其他严重肌肉骨骼疾病或器官功能障碍的参与者。我们采用WOMAC评分评估肌肉骨骼状况，采用SARC - F评分评估肌肉减少症风险。SARC - F评分≥4的患者存在肌肉减少症风险。血清元素浓度通过电感耦合等离子体质谱法进行分析。在相关性分析中确定临床评分和元素浓度对肌肉减少症风险的剂量 - 关系效应。使用单因素和多因素回归确定危险因素。使用R软件进行统计分析。
共有65例大骨节病患者和38例无大骨节病的参与者被纳入分析。经过倾向得分匹配后，两组的人口学特征具有可比性，且大骨节病组中SARC - F评分≥4的发生率更高（P = 0.002）。WOMAC评分在大骨节病组（P < 0.001）和非大骨节病组（P < 0.001）中分别与SARC - F评分相关。进一步分析证明大骨节病是肌肉减少症风险的独立危险因素（P = 0.014）。此外，在非大骨节病组中，高硒浓度与较低的肌肉减少症风险相关（P = 0.047），而在大骨节病组中未观察到这种关联（P = 0.239）。
大骨节病作为独立危险因素增加了患者发生肌肉减少症的风险。尽管高硒浓度在无大骨节病的参与者中与较低的肌肉减少症风险相关，但在大骨节病患者中未观察到这种关联。
